1
/
of
0
FDA Drug Approval, N020192, LAMISIL
FDA Drug Approval, N020192, LAMISIL
Regular price
$149.00 USD
Regular price
Sale price
$149.00 USD
Unit price
/
per
NDA: 020192
Company: NOVARTIS
Drug Name: LAMISIL
Active Ingredients: TERBINAFINE HYDROCHLORIDE
Strength: 1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage Form/Route: CREAM;TOPICAL
Action Date: 12/30/1992
Marketing Status: Discontinued
Submission Classification: Type 1 - New Molecular Entity
Company: NOVARTIS
Drug Name: LAMISIL
Active Ingredients: TERBINAFINE HYDROCHLORIDE
Strength: 1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage Form/Route: CREAM;TOPICAL
Action Date: 12/30/1992
Marketing Status: Discontinued
Submission Classification: Type 1 - New Molecular Entity
Couldn't load pickup availability
- Status: Pending Fast-Track Request
- Delivery: Approximately 1 to 2 weeks
NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.
View full details